45 results on '"Shevell, Diane"'
Search Results
2. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study
3. Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance
4. Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis
5. Determining a healthy reference range and factors potentially influencing PRO-C3 – A biomarker of liver fibrosis
6. Urinary CD80 Discriminates Among Glomerular Disease Types and Reflects Disease Activity
7. The Target of Ezetimibe Is Niemann-Pick C1-Like 1 (NPC1L1)
8. Cell Wall Alterations in the Arabidopsis emb30 Mutant
9. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study
10. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study
11. Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance
12. Pharmacokinetic, Pharmacodynamic, and Safety Profile of a Novel Anti‐CD28 Domain Antibody Antagonist in Healthy Subjects
13. BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial
14. A Region of the Ada DNA-Repair Protein Required for the Activation of ada Transcription is not Necessary for Activation of alkA
15. PRO‐C3, a Serological Marker of Fibrosis, During Childhood and Correlations With Fibrosis in Pediatric NAFLD
16. The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis
17. Collagen biology and non-invasive biomarkers of liver fibrosis
18. SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH
19. Profiling and targeting connective tissue remodeling in autoimmunity - A novel paradigm for diagnosing and treating chronic diseases
20. BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial.
21. Population Pharmacokinetic Analysis of BMS‐986166, a Novel Selective Sphingosine‐1‐Phosphate‐1 Receptor Modulator, and Exposure‐Response Assessment of Lymphocyte Counts and Heart Rate in Healthy Participants
22. Liver histopathology and extracellular matrix biomarkers in patients with advanced hepatic fibrosis from chronic hepatitis C who achieved a sustained virologic response
23. BMS-986263 (novel targeted lipid nanoparticle delivering HSP47 siRNA) safety and target engagement in patients with advanced hepatic fibrosis: week 36 results from a phase 2 randomized, double-blind, placebo-controlled trial
24. The safety and pharmacokinetics of a novel, selective S1P1R modulator in healthy participants
25. Collagen biology and non‐invasive biomarkers of liver fibrosis
26. Alteration of lysine 178 in the hinge region of the Escherichia coli Ada protein interferes with activation of ada, but not alkA, transcription
27. EMB30 is essential for normal cell division, cell expansion, and cell adhesion in Arabidopsis and encodes a protein that has similarity to Sec7
28. THU0190 THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF BMS-986166, A NOVEL, SELECTIVE, PARTIAL AGONIST OF THE SPHINGOSINE-1-PHOSPHATE (S1P) SUBTYPE 1 RECEPTOR IN HEALTHY PARTICIPANTS
29. Population Pharmacokinetic Analysis of BMS‐986166, a Novel Selective Sphingosine‐1‐Phosphate‐1 Receptor Modulator, and Exposure‐Response Assessment of Lymphocyte Counts and Heart Rate in Healthy Participants.
30. Evaluation of selective inhibitors of 11β-HSD1 for the treatment of hypertension
31. Discovery and Clinical Evaluation of MK‐8150, A Novel Nitric Oxide Donor With a Unique Mechanism of Nitric Oxide Release
32. Pharmacokinetic, Pharmacodynamic, and Safety Profile of a Novel Anti-CD28 Domain Antibody Antagonist in Healthy Subjects
33. Optical Imaging Biomarkers of Drug-Induced Vascular Injury
34. High-Throughput Doppler Toolbox for Preclinical Drug Development
35. Optical Imaging Biomarkers of Drug-Induced Vascular Injury.
36. Optical Imaging Biomarkers of Drug-Induced Vascular Injury.
37. Small Molecule Antagonists of Complement Receptor Type 3 Block Adhesion and Adhesion-Dependent Oxidative Burst in Human Polymorphonuclear Leukocytes
38. Deficiency in Inducible Nitric Oxide Synthase Results in Reduced Atherosclerosis in Apolipoprotein E-Deficient Mice
39. LBP17 - BMS-986263 (novel targeted lipid nanoparticle delivering HSP47 siRNA) safety and target engagement in patients with advanced hepatic fibrosis: week 36 results from a phase 2 randomized, double-blind, placebo-controlled trial.
40. Resistance to alkylation damage in Escherichia coli: Role of the Ada protein in induction of the adaptive response
41. High-Throughput Doppler Toolbox for Preclinical Drug Development
42. THU009 - Liver histopathology and extracellular matrix biomarkers in patients with advanced hepatic fibrosis from chronic hepatitis C who achieved a sustained virologic response.
43. Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance
44. Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis.
45. Small molecule antagonists of complement receptor type 3 block adhesion and adhesion-dependent oxidative burst in human polymorphonuclear leukocytes.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.